Guggenheim raised the firm’s price target on Galecto (GLTO) to $36 from $32 and keeps a Buy rating on the shares. The firm considers the ASH medical meeting “a positive development” because Incyte (INCY) reported INCA033989 data that de-risk the class for myelofibrosis, but showed a probability that efficacy in Type 2 patients has “been left on the table as a competitive opening” for DMR-001, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLTO: